Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599025 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29382463 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29398255 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29687581 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29484085 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30645711 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL38664164 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL12757436 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| Water SCHEMBL29698763 | 0.99 | MDM2 (0.53) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL1000225 | 0.96 | MDM2 (0.52) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250135026-A1 | Antibody Drug Conjugates | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-01 | — | — | US | disclosed |
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| CN-117980320-A | Bicyclic peptide inhibitors of interleukin-23 receptor | 詹森生物科技公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024049931-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4323017-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-7314726-B2 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314726-B2 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070149763-A1 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149763-A1 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1100816-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MDM2 3730/4885MDM4 934/4885TP53 3426/4885 |
| US-20260124317-A2 | Antibody Drug Conjugates | SLC3A2, SLC7A1, SLC43A1 | MDM2 892/4885MDM4 2164/4885TP53 268/4885 |
| US-20250135026-A1 | Antibody Drug Conjugates | CD22, FCGR2A, FCGR3B | MDM2 2955/4885MDM4 4243/4885TP53 2205/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | MDM2 4458/4885MDM4 4763/4885TP53 4077/4885 |
| US-20240116945-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | TOP1, TOP2A, TOP2B | MDM2 2396/4885MDM4 3321/4885TP53 39/4885 |
| US-20070149763-A1 | Beta secretase exosite binding peptides and methods for identifying beta secretase modulators | BACE1, BACE2, APP | MDM2 726/4885MDM4 1923/4885TP53 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.